202 related articles for article (PubMed ID: 22584487)
1. Is ⁶⁸Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?
Ambrosini V; Campana D; Nanni C; Cambioli S; Tomassetti P; Rubello D; Fanti S
Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1278-83. PubMed ID: 22584487
[TBL] [Abstract][Full Text] [Related]
2. The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors: real-world experience from two large neuroendocrine tumor centers.
Haidar M; Shamseddine A; Panagiotidis E; Jreige M; Mukherji D; Assi R; Abousaid R; Ibrahim T; Haddad MM; Vinjamuri S
Nucl Med Commun; 2017 Feb; 38(2):170-177. PubMed ID: 27922538
[TBL] [Abstract][Full Text] [Related]
3. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET.
Fanti S; Ambrosini V; Tomassetti P; Castellucci P; Montini G; Allegri V; Grassetto G; Rubello D; Nanni C; Franchi R
Biomed Pharmacother; 2008 Dec; 62(10):667-71. PubMed ID: 18358680
[TBL] [Abstract][Full Text] [Related]
5. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours.
Ambrosini V; Nanni C; Zompatori M; Campana D; Tomassetti P; Castellucci P; Allegri V; Rubello D; Montini G; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):722-7. PubMed ID: 20107793
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of 68Ga-DOTANOC PET/CT in patients with suspicion of neuroendocrine tumors: is its routine use justified?
Sharma P; Arora S; Mukherjee A; Pal S; Sahni P; Garg P; Khadgawat R; Thulkar S; Bal C; Kumar R
Clin Nucl Med; 2014 Jan; 39(1):37-43. PubMed ID: 24152621
[TBL] [Abstract][Full Text] [Related]
7. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
[TBL] [Abstract][Full Text] [Related]
8. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.
Ambrosini V; Tomassetti P; Castellucci P; Campana D; Montini G; Rubello D; Nanni C; Rizzello A; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1431-8. PubMed ID: 18418596
[TBL] [Abstract][Full Text] [Related]
9. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT.
Prasad V; Ambrosini V; Hommann M; Hoersch D; Fanti S; Baum RP
Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):67-77. PubMed ID: 19618183
[TBL] [Abstract][Full Text] [Related]
10. 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®).
Krausz Y; Freedman N; Rubinstein R; Lavie E; Orevi M; Tshori S; Salmon A; Glaser B; Chisin R; Mishani E; J Gross D
Mol Imaging Biol; 2011 Jun; 13(3):583-593. PubMed ID: 20652423
[TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of ⁶⁸Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: preliminary results from a single centre study.
Naswa N; Sharma P; Nazar AH; Agarwal KK; Kumar R; Ammini AC; Malhotra A; Bal C
Eur Radiol; 2012 Mar; 22(3):710-9. PubMed ID: 21971823
[TBL] [Abstract][Full Text] [Related]
12. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study.
Naswa N; Sharma P; Kumar A; Nazar AH; Kumar R; Chumber S; Bal C
AJR Am J Roentgenol; 2011 Nov; 197(5):1221-8. PubMed ID: 22021518
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of [
Yadav D; Ballal S; Yadav MP; Tripathi M; Roesch F; Bal C
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):860-869. PubMed ID: 31754796
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
[TBL] [Abstract][Full Text] [Related]
15. The added value of
Kazmierczak PM; Rominger A; Wenter V; Spitzweg C; Auernhammer C; Angele MK; Rist C; Cyran CC
Eur Radiol; 2017 Apr; 27(4):1676-1684. PubMed ID: 27436022
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
Naswa N; Sharma P; Suman Kc S; Lata S; Kumar R; Malhotra A; Bal C
Nucl Med Commun; 2012 Jul; 33(7):766-74. PubMed ID: 22531829
[TBL] [Abstract][Full Text] [Related]
17. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108
[TBL] [Abstract][Full Text] [Related]
18. Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.
Kaemmerer D; Peter L; Lupp A; Schulz S; Sänger J; Prasad V; Kulkarni H; Haugvik SP; Hommann M; Baum RP
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1659-68. PubMed ID: 21626438
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT.
Haug AR; Cindea-Drimus R; Auernhammer CJ; Reincke M; Beuschlein F; Wängler B; Uebleis C; Schmidt GP; Spitzweg C; Bartenstein P; Hacker M
Radiology; 2014 Feb; 270(2):517-25. PubMed ID: 24056402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
